Skip to main content
OpenTrials
Completed

NCT Number: NCT00537485

A Placebo-controlled Study for SPM 962 in Early Parkinson's Disease Patients

To investigate superiority of SPM 962 over placebo in early Parkinson's disease patients in a multi-center, placebo-controlled, double-blind study following once-daily multiple transdermal doses of SPM 962 within a range of 4.5 to 36.0 mg (12-week dose titration/maintenance period)

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Early Parkinson's Disease Basal Ganglia Diseases Brain Diseases Central Nervous System Diseases Movement Disorders Nervous System Diseases Neurodegenerative Diseases Parkinson Disease Parkinsonian Disorders Synucleinopathies

Age range

30 year–79 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2 / Phase 3

Primary location

Chubu Region, Japan

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subject diagnosed as having Parkinson's disease in accordance with "Diagnostic Criteria established by the Research Committee of MHLW-specified Intractable Neurodegenerative Diseases (1995)"
  • Subject is 30 years < > 80 years at the time of informed consent
  • Hoehn & Yahr stage 1- 3
  • Total of each sum score of UPDRS Part 2 and 3 is over 10 at screening test

Exclusion criteria

  • Subject has previously participated in a trial with SPM 962
  • Subject is on L-dopa treatment for total of over 6 months at the time of informed consent
  • Subject has psychiatric symptoms, e.g. confusion, hallucination, delusion, excitation, delirium, abnormal behavior at screening test and baseline
  • Subject has orthostatic hypotension
  • Subject has a history of epilepsy, convulsion and other
  • Subject has a complication of serious cardiac disorder/arrhythmia or has the history
  • Subject has arrhythmia and treated with class 1a anti-arrhythmic drugs (e.g. quinidine, procainamide etc.) or class 3 anti-arrhythmic drugs (e.g. amiodarone, sotalol etc.)
  • Subject has serious ECG abnormal at screening i.e.; 1) Subject has more than 450 msec of QTc values both in two measurements at screening test 2) Subject has more than 470 msec for females and more than 450 msec for males of mean QTc values of two measurements at baseline
  • Subject has congenital long QT syndrome
  • Subject has serum potassium of less than 3.5 mEq/L at screening test.
  • Subject has total bilirubin of 3.0 mg/dL and above or AST(GOT), ALT(GPT) greater than 2.5 times (or 100 IU/L and above) of the clinical laboratory's upper limit of the reference range at screening test
  • Subject has 30 mg/dL and above of BUN or 2.0 mg/dL and above of serum creatinine at screening test
  • Subject has a history of allergy to topical medicine, e.g. transdermal patch
  • Subject is pregnant, nursing, or is child bearing potential while the trial
  • Subject is receiving therapy with prohibited drug specified in the study protocol
  • Subject has a history of pallidotomy, thalamotomy, deep brain stimulation or fetal tissue transplant
  • Subject has dementia
  • Subject is unable to give consent
  • Subject is participating in another trial of an investigational drug or done so within 12 weeks prior to the initial treatment
  • Investigator judges that subject is inappropriate as a study subject with other reasons

Treatment and study plan

SPM 962

Drug

transdermal application, 1 time per day

Placebo

Drug

transdermal application, 1 time per day

Primary outcomes

  1. Change From Baseline to the End of Maintenance Period in Total of Each Sum Score of UPDRS Part 2 and Part 3

    Time frame: baseline, end of maintenance period

    Mean change (LOCF) from baseline to the end of maintenance period in total of each sum score of UPDRS Part 2 and Part 3.

    UPDRS is a scale for monitoring Parkinson's Disease-related disability and impairment. The UPDRS consists of the following four sub-scales. Part 1: Mentation, Part 2: Activities of Daily Living, Part 3: Motor, Part 4: Complications. Part 2 assesses 13 items and Part 3 assesses 14 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.

Secondary outcomes

  1. Efficacy Rate in Total of Each Sum Score of UPDRS Part 2 and Part 3

    Time frame: baseline, end of maintenance period

    Effective rate (percentage of subjects with 20% or 30% decrease) (LOCF) in total of each sum score of UPDRS Part 2 and Part 3 at the end of maintenance period

  2. Mean Change in UPDRS Part 2 Sum Score

    Time frame: Baseline, every two weeks

    Mean change (LOCF) from baseline in UPDRS Part 2 sum score at every two weeks after dosing.

    UPDRS sub-scale Part 2 assesses 13 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.

  3. Efficacy Rate in UPDRS Part 2 Sum Score

    Time frame: Baseline, every two weeks

    Effective rate (percentage of subjects with 20% or 30% decrease) (LOCF) in UPDRS Part 2 sum score at every two weeks after dosing.

  4. UPDRS Part 3 Sum Score

    Time frame: Baseline, every two weeks

    Mean change (LOCF) from baseline in UPDRS Part 3 sum score at every two weeks after dosing.

    UPDRS sub-scale Part 3 assesses 14 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.

  5. Efficacy Rate in UPDRS Part 3 Sum Score

    Time frame: Baseline, every two weeks

    Effective rate (percentage of subjects with 20% or 30% decrease) (LOCF) in UPDRS Part 2 sum score at every two weeks after dosing.

  6. UPDRS Part 1 Sum Score

    Time frame: Baseline, every two weeks

    MMean change (LOCF) from baseline in UPDRS Part 1 sum score at every two weeks after dosing.

    UPDRS sub-scale Part 1 assesses 4 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.

  7. UPDRS Part 4 Sum Score

    Time frame: Baseline, every two weeks

    Mean change (LOCF) from baseline in UPDRS Part 4 sum score at every two weeks after dosing.

    UPDRS sub-scale Part 4 assesses 11 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.

  8. Total of Each Sum Score of UPDRS Part 1, 2, 3, and 4

    Time frame: Baseline, every two weeks

    Mean change (LOCF) from baseline to the end of maintenance period in total of each sum score of UPDRS Part 1, 2, 3 and 4.

    UPDRS sub-scale Part 1, 2, 3, and 4 assess 4, 13, 14, and 11 items respectively. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.

  9. The Modified Hoehn and Yahr Stage

    Time frame: Baseline, end of maintenance period

    Mean change (LOCF) from baseline in the Modified Hoehn and Yahr Severity of Illness at the end of maintenance period. The Modified Hoehn and Yahr criteria are measured on the following 8-point scale for staging: 0, No signs of disease; 1, Unilateral disease; 1.5, Unilateral plus axial involvement; 2, Bilateral disease without impairment of balance; 2.5, Mild bilateral disease with recovery on pull test; 3, Mild to moderate bilateral disease, some postural instability, physically independent 4, Severe disability, still able to walk or stand unassisted; and 5, Wheelchair bound or bedridden unless aided.

Sponsors and collaborators

Lead sponsor

Otsuka Pharmaceutical Co., Ltd.

Industry

Registry information

Official study title

A Placebo-controlled Study for SPM 962 in Early Parkinson's Disease Patients With Non-concomitant Treatment of L-dopa

Important dates

Study start
2007
Primary completion
2009
Study completion
2009
First posted
Oct 1, 2007
Registry last updated
Mar 19, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.